← Search & browse all drugs
DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, PLAIN › Corticosteroids, potent (group III)
diflucortolone
D07AC06
Forms & Strengths
- Cream: 0.1%
- Ointment: 0.1%
- Fatty Ointment: 0.1%
Adult Dosing
- Apply thinly to affected skin areas 1 to 2 times daily
- Maximum duration of continuous treatment: usually up to 4 weeks
- Limit total body surface area treated to under 10% to minimize systemic absorption
Pediatric Dosing
- Safety and efficacy in children under 1 year not established
- Use with caution in children; apply sparingly for the shortest possible duration
- Avoid use under occlusive diapers or plastic pants
Indications
- Inflammatory skin diseases responsive to topical corticosteroids
- Eczema, including atopic dermatitis and contact dermatitis
- Psoriasis (excluding widespread plaque psoriasis)
Mechanism of Action
- High-potency synthetic topical corticosteroid (Group III)
- Binds to glucocorticoid receptors, inhibiting inflammatory cytokine transcription
- Reduces vasodilation, capillary permeability, and leukocyte infiltration in dermal tissues
Contraindications
- Hypersensitivity to diflucortolone or other corticosteroids
- Rosacea and perioral dermatitis
- Skin manifestations of viral infections (e.g., herpes simplex, varicella)
- Bacterial or fungal skin infections without concurrent anti-infective therapy
- Tuberculous or syphilitic skin lesions
Adverse Reactions
- Skin atrophy, striae, and telangiectasia with prolonged use
- Contact dermatitis and skin irritation
- Hypertrichosis and hypopigmentation
- Systemic absorption leading to hypothalamic-pituitary-adrenal axis suppression with extensive or occlusive use
Drug Interactions
- No significant pharmacokinetic drug-interactions expected with standard topical application
- Concomitant use with other immunosuppressive or corticosteroid therapies may increase systemic immunosuppressive effects
Curated Content: Needs Vetting Before Put to Clinical Use